AGM
RUBY

Alpine Global Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Alpine Global Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-76,814
Closed -$730K – 488
2019
Q4 		$730K Buy
+76,814
New +$743K 0.16% 115

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Alpine Global Management's RUBY Position: Q1 2020 in Review

Alpine Global Management sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2020, closing a stake of 76,814 shares — an estimated $730K sold.

Alpine Global Management first reported a position in RUBY in Q4 2019 and held it in 1 quarter. The position peaked at $730K in Q4 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q1 2020.

  • Alpine Global Management reported no remaining Rubius Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Alpine Global Management sold 76,814 Rubius Therapeutics, Inc shares in Q1 2020, an estimated $730K.
  • Alpine Global Management first reported a position in Rubius Therapeutics, Inc in Q4 2019 and held it in 1 quarter.
  • Alpine Global Management's Rubius Therapeutics, Inc position peaked at $730K in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.